These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

82 related articles for article (PubMed ID: 9137500)

  • 21. [The effect of sera of breast cancer patients on NK cell activity].
    Konjević G; Spuzić I
    Srp Arh Celok Lek; 1995; 123(9-10):227-31. PubMed ID: 17974436
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Circulating soluble Fas concentration in breast cancer patients.
    Ueno T; Toi M; Tominaga T
    Clin Cancer Res; 1999 Nov; 5(11):3529-33. PubMed ID: 10589768
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Predictive relevance of soluble CD44v6 serum levels for the responsiveness to second line hormone- or chemotherapy in patients with metastatic breast cancer.
    Kopp R; Classen S; Wolf H; Gholam P; Possinger K; Wilmanns W
    Anticancer Res; 2001; 21(4B):2995-3000. PubMed ID: 11712800
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Expression of sialyl lewis X, sialyl Lewis A, E-cadherin and cathepsin-D in human breast cancer: immunohistochemical analysis in mammary carcinoma in situ, invasive carcinomas and their lymph node metastasis.
    Jeschke U; Mylonas I; Shabani N; Kunert-Keil C; Schindlbeck C; Gerber B; Friese K
    Anticancer Res; 2005; 25(3A):1615-22. PubMed ID: 16033070
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Increased plasma soluble adhesion molecules; ICAM-1, VCAM-1, and E-selectin levels in patients with slow coronary flow.
    Turhan H; Saydam GS; Erbay AR; Ayaz S; Yasar AS; Aksoy Y; Basar N; Yetkin E
    Int J Cardiol; 2006 Apr; 108(2):224-30. PubMed ID: 16002164
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Carbohydrate antigen sialyl Lewis a--its pathophysiological significance and induction mechanism in cancer progression.
    Kannagi R
    Chang Gung Med J; 2007; 30(3):189-209. PubMed ID: 17760270
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Detection of occult metastatic breast cancer cells in blood by a multimolecular marker assay: correlation with clinical stage of disease.
    Taback B; Chan AD; Kuo CT; Bostick PJ; Wang HJ; Giuliano AE; Hoon DS
    Cancer Res; 2001 Dec; 61(24):8845-50. PubMed ID: 11751407
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Soluble P-selectin - a marker of platelet activation and vessel wall injury: increase of soluble P-selectin in plasma of patients with myocardial infarction, massive atherosclerosis and primary pulmonary hypertension].
    Semenov AV; Kogan-Ponomarev MIa; Ruda MIa; Komarov AL; Panchenko EP; Chazova IE; Mazurov AV
    Ter Arkh; 2000; 72(4):15-20. PubMed ID: 10833791
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Inhibition of colon carcinoma cell lung colony formation by a soluble form of E-selectin.
    Mannori G; Santoro D; Carter L; Corless C; Nelson RM; Bevilacqua MP
    Am J Pathol; 1997 Jul; 151(1):233-43. PubMed ID: 9212748
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Elevated plasma TGF-beta1 levels correlate with decreased survival of metastatic breast cancer patients.
    Ivanović V; Demajo M; Krtolica K; Krajnović M; Konstantinović M; Baltić V; Prtenjak G; Stojiljković B; Breberina M; Nesković-Konstantinović Z; Nikolić-Vukosavljević D; Dimitrijević B
    Clin Chim Acta; 2006 Sep; 371(1-2):191-3. PubMed ID: 16650397
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Clinical significance of circulating soluble E-selectin (ELAM-1) in patients with cancers].
    Mitsuoka C; Kannagi R
    Nihon Rinsho; 1995 Jul; 53(7):1770-5. PubMed ID: 7543167
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Soluble adhesion molecules and anti-endothelial cell antibodies in patients with rheumatoid arthritis complicated by peripheral neuropathy.
    Salih AM; Nixon NB; Dawes PT; Mattey DL
    J Rheumatol; 1999 Mar; 26(3):551-5. PubMed ID: 10090161
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Gene expression of E-selectin in tissue and its protein level in serum of breast cancer patients.
    Shaker OG; Ay El-Deen MA; Abd El-Rahim MT; Talaat RM
    Tumori; 2006; 92(6):524-30. PubMed ID: 17260494
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Significance of soluble endothelial molecule E-selectin in patients with breast cancer.
    Hebbar M; Peyrat JP
    Int J Biol Markers; 2000; 15(1):15-21. PubMed ID: 10763135
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Serum soluble vascular cell adhesion molecule-1: role as a surrogate marker of angiogenesis.
    Byrne GJ; Ghellal A; Iddon J; Blann AD; Venizelos V; Kumar S; Howell A; Bundred NJ
    J Natl Cancer Inst; 2000 Aug; 92(16):1329-36. PubMed ID: 10944555
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Effects of carcinostatic agents in the hematogenous metastasis of cancer].
    Nakashio T; Akiyama S; Kasai Y; Ito K; Takagi H; Narita T; Mitsuoka C; Kannagi R
    Gan To Kagaku Ryoho; 1997 Mar; 24(5):591-6. PubMed ID: 9087293
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Serum levels of soluble E-selectin are associated with the clinical course of metastatic disease in patients with liver metastases from breast cancer.
    Eichbaum MH; de Rossi TM; Kaul S; Bastert G
    Oncol Res; 2004; 14(11-12):603-10. PubMed ID: 15667001
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Role of serum E-selectin (ELAM-1) and inflammatory parameters in patients with renal cell carcinoma].
    Muraki J; Kobayashi M; Sugaya Y; Hashimoto S; Morita T; Kobayashi Y; Tokue A
    Nihon Hinyokika Gakkai Zasshi; 1996 May; 87(5):831-41. PubMed ID: 8691708
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Elevated serum E-selectin in patients with liver metastases of colorectal cancer.
    Wittig BM; Kaulen H; Thees R; Schmitt C; Knolle P; Stock J; Meyer zum Büschenfelde KH; Dippold W
    Eur J Cancer; 1996 Jun; 32A(7):1215-8. PubMed ID: 8758256
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Soluble E-selectin in cancer patients as a marker of the therapeutic efficacy of CM101, a tumor-inhibiting anti-neovascularization agent, evaluated in phase I clinical trail.
    Wamil BD; Thurman GB; Sundell HW; DeVore RF; Wakefield G; Johnson DH; Wang YF; Hellerqvist CG
    J Cancer Res Clin Oncol; 1997; 123(3):173-9. PubMed ID: 9119883
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.